Tafinlar/Mekinist

Pre-clinicalRecruiting

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Conditions

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Trial Timeline

Feb 9, 2024 → Dec 31, 2031

NCT ID

NCT06262919

About Tafinlar/Mekinist

Tafinlar/Mekinist is a pre-clinical stage product being developed by Novartis for BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06262919. Target conditions include BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor.

What happened to similar drugs?

0 of 2 similar drugs in BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor were approved

Approved (0) Terminated (1) Active (1)

🔄Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3

❌Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06262919	Pre-clinical	Recruiting	Feb 9, 2024	Dec 31, 2031	BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Competing Products

13 competing products in BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

See all competitors

Product	Company	Stage	Hype Score
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
TMZ + E7016	Eisai	Phase 2	27
Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil	Ono Pharmaceutical	Phase 3	40
encorafenib + Binimetinib + Cetuximab	Ono Pharmaceutical	Phase 2	35
Encorafenib + Cetuximab + FOLFIRI	Merck	Phase 2	35
BKM120 Combined with Vemurafenib (PLX4032)	Novartis	Phase 1/2	32
Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab	Novartis	Phase 1	21
Cobimetinib + Atezolizumab + Pembrolizumab	Roche	Phase 3	32
LGX818 + MEK162 + LEE011	Pfizer	Phase 1/2	32
MEK162	Pfizer	Phase 2	35
Encorafenib + Binimetinib + cemiplimab+fianlimab	Regeneron Pharmaceuticals	Phase 2	42
Plixorafenib + Cobicistat 150 MG [Tybost]	Brain Biotech	Phase 1	26
Dabrafenib + Trametinib + Hydroxychloroquine	Brain Biotech	Phase 1/2	26